Date: Sunday, November 5, 2017
Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: In a previous study, we identify a potential role of anti-RNP/Sm in combination with LA as risk factor for thrombosis. We aimed to validate this association
Methods: Case-control study of patients with SLE who presented thrombosis after SLE diagnosis and controls with SLE without thrombosis. All patients fulfilled ³ 4 American College of Rheumatology revised and updated classification criteria for SLE. Comorbidities, traditional risk factors, clinical variables, disease activity and treatment were evaluated. Also, a blood sample was drawn to determine antiphospholipid (aPL) and anti-RNP/Sm antibodies. Statistical analysis: Differences between groups were evaluated with the Student t-test or Mann-Whitney U test for continuous variables; Chi-square or Fisher’s exact test for categorical variables. Univariate logistic regression analyses and multivariate analyses were performed. Odds-ratio (OR) and 95% confidence intervals (95% CI) were calculated
Results: 63 cases and 63 controls were studied, 88% women, median age of 40 years and disease duration of 135 months at study inclusion. No differences were found between groups regarding age, comorbidities, or clinical characteristics at SLE diagnosis. Patients with thrombosis were more frequently positive for anti-RNP/Sm (83% vs 62%, p=0.001); IgG aCL (29% vs 11%, p=0.02); IgG anti-B2GPI (21% vs 13%, p=0.02); IgM anti-B2GPI (p=0.02); LA (62% vs 19%, p<0.001); the combination of anti-RNP/Sm + LA (52% vs 14%, p<0.001), and aPL triple marker (17% vs 2%, p=0.002), compared to controls. The combination of anti-RNP/Sm + LA (OR 5.98, 95% CI 2.17-16.47, p=0.001); SLEDAI-2K (OR 1.18, 95% CI 1.04-1.32, p=0.007), and prednisone dose (OR 1.08, 95% CI 1.03-1.12, p<0.001) were independently associated with thrombosis.
Conclusion: This study confirmed an independent association between the combination of anti-RNP/Sm antibodies and LA with thrombosis. Further studies to identify potential pathogenesis mechanisms of the presence of anti-RNP/Sm and thrombosis are needed
To cite this abstract in AMA style:Zamora-Medina MC, Hinojosa-Azaola A, Núñez-Álvarez C, Romero-Diaz J. Anti-RNP/Sm Antibodies Plus Lupus Anticoagulant As Risk Factor for Thrombosis in Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/anti-rnpsm-antibodies-plus-lupus-anticoagulant-as-risk-factor-for-thrombosis-in-patients-with-systemic-lupus-erythematosus/. Accessed October 20, 2020.
« Back to 2017 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-rnpsm-antibodies-plus-lupus-anticoagulant-as-risk-factor-for-thrombosis-in-patients-with-systemic-lupus-erythematosus/